Precision Digital Health
Precision Digital Health is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A double-blind, randomized, placebo-controlled, dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia
Sponsor Recordati AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Open-Label, Single Ascending Dose, First-In-Human Study to Assess Safety and Tolerability of Endoscopic Ultrasound-Guided Pancreatic Infusion of RJVA-001 in Adults With Inadequately Controlled Type 2 Diabetes on Multiple Glucose-Lowering Agents
Sponsor Fractyl Health Inc.
- Start (EU)
- Latest update
- Estimated end
C3651011 - A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 4-ARM STUDY TO INVESTIGATE SYMPTOMS, FUNCTION, HEALTH-RELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes
Sponsor Immunocore Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)
Sponsor Sab Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults, adolescents and children with newly diagnosed type 1 diabetes on insulin therapy
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination with Insulin Aspart, in Adults with Type 1 Diabetes
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults with Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype
Sponsor Diamyd Medical AB
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients with Congenital Hyperinsulinism
Sponsor Rezolute Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Precision Digital Health?
The 2026-10-09 snapshot links Precision Digital Health to 9 distinct CTIS trials. Recorded services include Electronic data capture, Activity monitor Insight watches to be provided to participants to monitor their activities, BGM and CGM device services, Central Glucose Monitoring (CGM) , among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Precision Digital Health?
The most frequently recorded therapeutic areas are Endocrinology, Metabolic Disorders, Gastroenterology. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Precision Digital Health conducted?
The linked trials record locations in 20 countries, including Germany, Spain, Poland, France, Austria. These are trial locations, not confirmed office locations or countries where Precision Digital Health delivered services.
What can this page tell me about Precision Digital Health's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Precision Digital Health. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Precision Digital Health Inc.